Named on 4 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2022-12-22 to 2026-09-29
ROUNDS
4
led 1, joined 3
LED ROUNDS · USD
$3.6M
across 1 round · 1 co-led, split evenly
CO-INVESTORS
14
most often with Navigare Ventures
Named on 4 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2022-12-22 to 2026-09-29
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AnaCardio A clinical-stage biopharmaceutical company developing novel therapies for heart failure | Series B Verified against 1 of 17 sources | $71.0M | 2026-09-29 | [ PART ] |
Pixelgen Technologies Pixelgen Technologies sells innovative tools and technologies for spatial analysis of cell surface architecture, primarily for the biotech sector. | Series B Verified against 2 of 3 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $15.5M | 2026-08-21 | [ PART ] |
Pixelgen Technologies Pixelgen Technologies sells innovative tools and technologies for spatial analysis of cell surface architecture, primarily for the biotech sector. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $7.3M | 2023-10-09 | [ LEAD ] |
Enginzyme Enginzyme sells enzyme-based biomanufacturing solutions for cleaner and more efficient manufacturing processes, targeting the biotech sector. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $22.3M | 2022-12-22 | [ PART ] |